| COVID-19 |
1 |
1 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.88 |
| Healthcare and Medical Technology |
0 |
0.34 |
| Clinical Research |
0 |
0.99 |
| Child |
0 |
0.22 |
| Fatigue |
0 |
0.18 |
| Brain |
0 |
0.15 |
| Vaccines |
0 |
0.15 |
| Pain Management |
0 |
0.14 |
| Patient Safety |
0 |
0.12 |
| Heart |
0 |
0.11 |
| Travel Medicine |
0 |
0.11 |
| Lung |
0 |
0.07 |
| Muscle |
0 |
0.07 |
| New York |
0 |
0.07 |
| Treatment Guidelines |
0 |
0.05 |
| ADHD |
0 |
0.04 |
| Adverse Effects |
0 |
0.04 |
| Antiviral Agents |
0 |
0.04 |
| Blood |
0 |
0.04 |
| Clinical Guidelines |
0 |
0.04 |
| Drug Interaction |
0 |
0.04 |
| Experimental Drug |
0 |
0.04 |
| Illinois |
0 |
0.04 |
| Immunization |
0 |
0.04 |
| Kidney |
0 |
0.04 |
| Muscular Atrophy |
0 |
0.04 |
| Myasthenia Gravis |
0 |
0.04 |
| Ohio |
0 |
0.04 |
| Orbit |
0 |
0.04 |
| Pain |
0 |
0.04 |
| Physical Medicine and Rehabilitation (PMR) |
0 |
0.04 |
| Primary Care |
0 |
0.04 |
| Sleep |
0 |
0.04 |
| Sleep Disorders |
0 |
0.04 |
| Texas |
0 |
0.04 |
| Weakness |
0 |
0.04 |